PMID- 22865778
OWN - NLM
STAT- MEDLINE
DCOM- 20130620
LR  - 20220321
IS  - 1569-8041 (Electronic)
IS  - 0923-7534 (Linking)
VI  - 24
IP  - 1
DP  - 2013 Jan
TI  - The proportion of tumor-stroma as a strong prognosticator for stage II and III 
      colon cancer patients: validation in the VICTOR trial.
PG  - 179-85
LID - 10.1093/annonc/mds246 [doi]
AB  - BACKGROUND: The intra-tumor stroma percentage in colon cancer (CC) patients has 
      previously been reported by our group as a strong independent prognostic 
      parameter. Patients with a high stroma percentage within the primary tumor have a 
      poor prognosis. PATIENTS AND METHODS: Tissue samples from the most invasive part 
      of the primary tumor of 710 patients (52% Stage II, 48% Stage III) participating 
      in the VICTOR trial were analyzed for their tumor-stroma percentage. Stroma-high 
      (>50%) and stroma-low (</=50%) groups were evaluated with respect to survival 
      times. RESULTS: Overall and disease-free survival times (OS and DFS) were 
      significantly lower in the stroma-high group (OS P<0.0001, hazard ratio 
      (HR)=1.96; DFS P<0.0001, HR=2.15). The 5-year OS was 69.0% versus 83.4% and DFS 
      58.6% versus 77.3% for stroma-high versus stroma-low patients. CONCLUSION: This 
      study confirms the intra-tumor stroma ratio as a prognostic factor. This 
      parameter could be a valuable and low cost addition to the TNM status and next to 
      current high-risk parameters such as microsatellite instability status used in 
      routine pathology reporting. When adding the stroma-parameter to the ASCO 
      criteria, the rate of 'undertreated' patients dropped from 5.9% to 4.3%, the 
      'overtreated' increased with 6.8% but the correctly classified increased with an 
      additional 14%.
FAU - Huijbers, A
AU  - Huijbers A
AD  - Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
FAU - Tollenaar, R A E M
AU  - Tollenaar RA
FAU - v Pelt, G W
AU  - v Pelt GW
FAU - Zeestraten, E C M
AU  - Zeestraten EC
FAU - Dutton, S
AU  - Dutton S
FAU - McConkey, C C
AU  - McConkey CC
FAU - Domingo, E
AU  - Domingo E
FAU - Smit, V T H B M
AU  - Smit VT
FAU - Midgley, R
AU  - Midgley R
FAU - Warren, B F
AU  - Warren BF
FAU - Johnstone, E C
AU  - Johnstone EC
FAU - Kerr, D J
AU  - Kerr DJ
FAU - Mesker, W E
AU  - Mesker WE
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PT  - Validation Study
DEP - 20120802
PL  - England
TA  - Ann Oncol
JT  - Annals of oncology : official journal of the European Society for Medical 
      Oncology
JID - 9007735
SB  - IM
MH  - Colonic Neoplasms/*pathology
MH  - Double-Blind Method
MH  - Humans
MH  - Prognosis
MH  - Stromal Cells/*pathology
MH  - Survival Analysis
EDAT- 2012/08/07 06:00
MHDA- 2013/06/21 06:00
CRDT- 2012/08/07 06:00
PHST- 2012/08/07 06:00 [entrez]
PHST- 2012/08/07 06:00 [pubmed]
PHST- 2013/06/21 06:00 [medline]
AID - S0923-7534(19)37042-5 [pii]
AID - 10.1093/annonc/mds246 [doi]
PST - ppublish
SO  - Ann Oncol. 2013 Jan;24(1):179-85. doi: 10.1093/annonc/mds246. Epub 2012 Aug 2.